PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 15, 20240 citationsOpen Access

Supplementary Figure 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

View Full Paper
HSHarshabad SinghPSPranshu SahgalKKKevin S. Kapner

Key Points

Key points are not available for this paper at this time.

Abstract

Supplementary Figure 4. RAS/RAF co-altered, HER2 amplified CRC reflects a unique genomic subset with HER2 intratumoral heterogeneity.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Singh et al. (2024) studied this question.

synapsesocial.com/papers/68e6f2a2b6db64358766d1c8https://doi.org/10.1158/1078-0432.25603657.v1
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer2024
  2. 2Supplementary Figure 2 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer2024
  3. 3Supplementary Figure 2 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer2024
  4. 4Supplementary Figure 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer2024
  5. 5Supplementary Figure 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer2024